ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

NCI Plans Two New RFAs For Stimulus Funds

March 6, 2009

Bypass Budget For FY 1992 Shown In Chart

May 18, 1990

FDA Tightens Conflict of Interest Rules For Advisors.

March 23, 2007

Rall Supports Animal Tests; Carcinogenesis Reports Summarized

May 13, 1977

Breast surgeon and advocate Susan Love weds surgeon Helen Cooksey in San Francisco.

February 20, 2004

In Brief: Rogers On AHF Board; GAO Says Legislation May Needed For Hospice Reimbursement

March 23, 1979